KIRSTEN YEZZI: Open Payments
NPI 1659874535 · RICHMOND, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$621 in 30 payments from 10 companies in 2025. Trend: 2023 $269 · 2024 $519 · 2025 $621
Food & beverage: $621
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 10 | $175 |
| GENZYME CORPORATION | 3 | $87 |
| Regeneron Healthcare Solutions, Inc. | 3 | $76 |
| UCB, Inc. | 3 | $66 |
| Incyte Corporation | 3 | $65 |
| Janssen Biotech, Inc. | 3 | $56 |
| Lilly USA, LLC | 2 | $35 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 1 | $27 |
| Pierre Fabre Pharmaceuticals, Inc. | 1 | $19 |
| Galderma Laboratories, L.P. | 1 | $15 |
Products named: DUPIXENT, COSENTYX, Bimzelx, OPZELURA, TREMFYA, EBGLYSS, Winlevi, Rhapsido.
Industry payments across VA — which companies pay providers there.
